HPV and Pap Testing Market Opportunity Analysis, 2018-2026
HPV and Pap Testing Market
HPV stands for human papillomavirus, which constitutes a group of more than 150 related viruses. Every HPV virus has a number or a type. HPVs are attracted to only a specific cell type known as squamous epithelial cells and the viruses can live only in these cells. Some of the human papillomavirus can cause non-cancerous tumors while others can lead to cancer, which includes cancer of the cervix, vagina, vulva, anus, penis, and parts of mouth and throat that comprises mostly of the moist skin in the body. These types of HPVs are considered to be mucosal, as they invade in the living cells on mucosal surfaces.
Click To Continue Reading on HPV and Pap Testing Market
Diagnosis and treatment of the abnormal cells developing in the cervix help in the prevention of cervical cancer. The two most common tests employed to check the behavior of cervical cells are HPV and Pap tests. The Pap test is a simple smear test, which provides an effective screening measure to determine whether the cervical cells are normal or abnormal. HPV testing is performed to screen for human papillomavirus in the cervix that can lead to cervical cancer. A person observed with abnormal cells through Pap test is recommended to opt for HPV testing for further evaluation of cervical cancer. According to the National Cervical Cancer Coalition 2017, around 12,000 women are diagnosed with cervical cancer per year in the U.S. Moreover, the American Sexual Health Association (ASHA) suggests that cervical cancer is amongst one of the most preventable types of cancer. These cancers can be prevented through early detection and treatment of abnormal cell changes that occurs in the cervix prior to the development of cervical cancer cells.
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1733
Moreover, technological advancements in improving the existing accuracy of HPV testing is also expected to drive growth of global HPV testing and Pap test market. For instance, in April 2014, Roche Molecular Systems received FDA approval for Cobas HPV test as a primary screening test that would facilitate mitigation of late-stage survival cancer. However, the inaccuracy of smear based Pap test leading to low reliability is expected to hamper growth of the global HPV and Pap testing market.
Qiagen N.V., Abbott Laboratories, Becton, Dickinson & Company, Hologic, Inc., Quest Diagnostics, Femasys, Inc., Roche Diagnostics, Arbor Vita Corporation, Onco Health Corporation, Seegene, Inc., and others.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Visit Blog: http://healthcaremarketconsulting.blogspot.com/